Published in J Immunol on June 04, 2010
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
Regulation of proteasome activity in health and disease. Biochim Biophys Acta (2013) 1.52
Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Dig Dis Sci (2015) 1.41
Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification. J Clin Invest (2017) 1.40
The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta (2011) 1.36
Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci (2012) 1.36
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med (2011) 1.12
A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus. PLoS One (2011) 1.08
The immunoproteasome as a target in hematologic malignancies. Semin Hematol (2012) 0.97
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med (2014) 0.95
A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer (2012) 0.93
Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des (2013) 0.92
Impairment of immunoproteasome function by β5i/LMP7 subunit deficiency results in severe enterovirus myocarditis. PLoS Pathog (2011) 0.92
TLR4 mediates the impairment of ubiquitin-proteasome and autophagy-lysosome pathways induced by ethanol treatment in brain. Cell Death Dis (2014) 0.90
The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol (2012) 0.90
Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis. Int J Inflam (2012) 0.86
Proteomic identification of immunoproteasome accumulation in formalin-fixed rodent spinal cords with experimental autoimmune encephalomyelitis. J Proteome Res (2012) 0.85
A key role for NF-κB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions. Clin Dev Immunol (2012) 0.85
Inhibition of immunoproteasome reduces infarction volume and attenuates inflammatory reaction in a rat model of ischemic stroke. Cell Death Dis (2015) 0.83
Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNΓ. PLoS One (2014) 0.83
New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells. J Immunol Res (2015) 0.82
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice. Clin Exp Immunol (2012) 0.82
Cytokine-induced oxidative stress in cardiac inflammation and heart failure-how the ubiquitin proteasome system targets this vicious cycle. Front Physiol (2013) 0.81
Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Curr Opin Chem Biol (2014) 0.80
Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A (2016) 0.80
β5i subunit deficiency of the immunoproteasome leads to reduced Th2 response in OVA induced acute asthma. PLoS One (2013) 0.79
mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell (2016) 0.79
Prostaglandin E2 Production and T Cell Function in Mouse Adenovirus Type 1 Infection following Allogeneic Bone Marrow Transplantation. PLoS One (2015) 0.78
Enhanced inflammatory potential of CD4+ T-cells that lack proteasome immunosubunit expression, in a T-cell transfer-based colitis model. PLoS One (2014) 0.77
Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice. Sci Rep (2016) 0.77
Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. Oncotarget (2017) 0.77
Proteasome β5i Subunit Deficiency Affects Opsonin Synthesis and Aggravates Pneumococcal Pneumonia. PLoS One (2016) 0.76
No evidence for immunoproteasomes in chicken lymphoid organs and activated lymphocytes. Immunogenetics (2014) 0.76
Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy. Mol Ther (2016) 0.75
Immunoproteasome subunit LMP7 Deficiency Improves Obesity and Metabolic Disorders. Sci Rep (2015) 0.75
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes. Front Immunol (2017) 0.75
Emerging role of immunoproteasomes in pathophysiology. Immunol Cell Biol (2016) 0.75
Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc Natl Acad Sci U S A (2017) 0.75
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit. ACS Med Chem Lett (2017) 0.75
Soluble bioactive microbial mediators regulate proteasomal degradation and autophagy to protect against inflammation-induced stress. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. Oncotarget (2017) 0.75
Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases. J Autoimmun (2017) 0.75
Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy. Eur J Microbiol Immunol (Bp) (2017) 0.75
The immunoproteasome is induced by cytokines and regulates apoptosis in human islets. J Endocrinol (2017) 0.75
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood (2002) 2.61
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res (2011) 2.56
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum (2012) 2.03
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med (2002) 1.86
Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell (2012) 1.83
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell (2013) 1.74
Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol (2009) 1.67
FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol (2005) 1.53
The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol (2012) 1.52
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem (2009) 1.50
CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood (2003) 1.46
Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol (2006) 1.40
Analysis and expression of a cloned pre-T cell receptor gene. Science. 1994. 266: 1208-1212. J Immunol (2009) 1.39
Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos (2011) 1.35
Substantial reduction of naïve and regulatory T cells following traumatic stress. Brain Behav Immun (2009) 1.33
Inducible activation of Ras and Raf in adult epidermis. Cancer Res (2003) 1.29
NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J Biol Chem (2004) 1.28
TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine (2008) 1.26
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood (2010) 1.25
Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol (2006) 1.25
An altered T cell repertoire in MECL-1-deficient mice. J Immunol (2006) 1.25
UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem (2007) 1.25
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol (2004) 1.21
Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem (2003) 1.18
PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev (2005) 1.15
Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine (2003) 1.14
Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel (2008) 1.14
The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J Cell Sci (2008) 1.13
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol (2010) 1.11
Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One (2011) 1.10
Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09
Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry (2013) 1.09
Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol (2005) 1.06
Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine (2005) 1.05
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother (2006) 1.04
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol (2011) 1.04
Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood (2008) 1.04
Method for analyzing signaling networks in complex cellular systems. Proc Natl Acad Sci U S A (2004) 1.03
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther (2012) 1.02
Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol (2007) 1.01
Complex changes in cellular inositol phosphate complement accompany transit through the cell cycle. Biochem J (2004) 1.01
Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol (2012) 1.01
A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol (2004) 0.99
Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain (2013) 0.99
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol (2013) 0.98
Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target (2009) 0.97
Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett (2009) 0.97
USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat Commun (2010) 0.96
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J Immunol (2010) 0.96
The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10. J Biol Chem (2006) 0.95
Invasive aspergillosis in non-neutropenic patients. Eur J Intern Med (2009) 0.95
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med (2014) 0.95
Gene expression profile of bladder tissue of patients with ulcerative interstitial cystitis. BMC Genomics (2009) 0.95
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res (2012) 0.94
The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer (2010) 0.94
The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol (2009) 0.93
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy (2012) 0.92
Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol (2010) 0.92
The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J Cell Sci (2012) 0.92
Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J Control Release (2012) 0.92
Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. J Cell Sci (2008) 0.92
No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes. Eur J Immunol (2007) 0.91
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol (2014) 0.89
Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med (2005) 0.89
CD8- dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol (2011) 0.89
Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J Immunol (2012) 0.89
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica (2013) 0.89
FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. Nat Commun (2012) 0.88
Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods (2004) 0.88
Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C. Int Urogynecol J (2013) 0.88
Ubiquitylation of the chemokine receptor CCR7 enables efficient receptor recycling and cell migration. J Cell Sci (2012) 0.87
NUB1 modulation of GSK3β reduces tau aggregation. Hum Mol Genet (2012) 0.86
FAT10 : Activated by UBA6 and Functioning in Protein Degradation. Subcell Biochem (2010) 0.86
Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol (2011) 0.86
The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials (2006) 0.85
Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit. Mol Immunol (2012) 0.85
A novel cytosolic class I antigen-processing pathway for endoplasmic-reticulum-targeted proteins. EMBO Rep (2007) 0.85
The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol (2011) 0.85
Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut (2006) 0.84
FAT10ylation as a signal for proteasomal degradation. Biochim Biophys Acta (2013) 0.84
Endocrine disrupting alkylphenols: structural requirements for their adverse effects on Ca2+ pumps, Ca2+ homeostasis & Sertoli TM4 cell viability. Chem Biol Interact (2008) 0.83
Inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by flavonoids: a quantitative structure-activity relationship study. IUBMB Life (2008) 0.83
Heterozygous disruption of renal outer medullary potassium channel in rats is associated with reduced blood pressure. Hypertension (2013) 0.81
Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. Brain Behav Immun (2010) 0.81
Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol (2012) 0.81
Quantitative analysis of gene expression relative to 18S rRNA in carcinoma samples using the LightCycler instrument and a SYBR GreenI-based assay: determining FAT10 mRNA levels in hepatocellular carcinoma. Methods Mol Biol (2008) 0.80
An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Mol Ther (2011) 0.80
Diagnostic performance in a primary referral hospital assessed by autopsy: evolution over a ten-year period. Eur J Intern Med (2009) 0.80